Department of Internal Medicine, Division of Hematology and Oncology, American University of Beirut Medical Center, Beirut, Lebanon.
Clin Appl Thromb Hemost. 2010 Aug;16(4):472-4. doi: 10.1177/1076029609332110. Epub 2009 Feb 16.
Myeloproliferative disorders and the inherited thrombophilias have been described as the main causes underlying the Budd-Chiari syndrome. Moreover, the presence of the JAK2V617F was associated with a higher frequency of Budd-Chiari syndrome in patients who have overt or even latent myeloproliferative disorder. We herein describe a 28-year-old woman who was diagnosed with Budd-Chiari syndrome and later developed an overt myeloproliferative disorder. The patient was found to carry both the JAK2V617F and the prothrombin G20210A mutation in the heterozygous form. The significance of the chronology of diagnosis is highlighted.
骨髓增殖性疾病和遗传性血栓形成倾向已被描述为布加综合征的主要病因。此外,JAK2V617F 的存在与显性或隐性骨髓增殖性疾病患者中布加综合征的更高发生率相关。本文描述了一位 28 岁的女性,她被诊断为布加综合征,随后发展为显性骨髓增殖性疾病。该患者被发现存在 JAK2V617F 和凝血酶原 G20210A 突变的杂合形式。诊断时间顺序的意义被强调。